Clinical Trials Browser

Phase 2 × Neurofibrosarcoma × Sirolimus × Clear all

NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Completed

21 enrolled 12 charts

Neurofibromatosis 1, Neurofibrosarcoma